2010, 1st ed., Essential clinical skills for nurses, ISBN 140518163X, x, 309
The safe and effective management of medicines is an essential clinical skill, accounting for up to 40% of a nurse’s time within practice. Medicines Management...
Medication Errors | Drugs | Administration | Nursing | Nurse's Role | Therapeutics | Drug Therapy | prevention & control | Drug Monitoring | Prescriptions | Therapeutics–Handbooks, manuals, etc | Medical | Nursing–Handbooks, manuals, etc | Critical & Intensive Care | Drugs–Administration–Handbooks, manuals, etc | Handbooks, manuals, etc
Medication Errors | Drugs | Administration | Nursing | Nurse's Role | Therapeutics | Drug Therapy | prevention & control | Drug Monitoring | Prescriptions | Therapeutics–Handbooks, manuals, etc | Medical | Nursing–Handbooks, manuals, etc | Critical & Intensive Care | Drugs–Administration–Handbooks, manuals, etc | Handbooks, manuals, etc
Book
American Heart Journal, ISSN 0002-8703, 2016, Volume 182, pp. 28 - 35
Background Non-vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to...
Cardiovascular | INTRAVENOUS THROMBOLYSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN ANTICOAGULATION | TISSUE-PLASMINOGEN ACTIVATOR | WARFARIN | ACUTE ISCHEMIC-STROKE | GUIDELINES | INTRACEREBRAL HEMORRHAGE | RISK SCORE | HEALTH-CARE PROFESSIONALS | INTRACRANIAL HEMORRHAGE | United States - epidemiology | Dabigatran - adverse effects | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Humans | Stroke - diagnosis | Warfarin - adverse effects | Male | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Medication Therapy Management - standards | Warfarin - administration & dosage | Rivaroxaban - administration & dosage | Thiazoles - adverse effects | Pyridones - administration & dosage | Pyridines - adverse effects | Rivaroxaban - adverse effects | Adult | Female | Registries | Stroke - therapy | Pyrazoles - adverse effects | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Emergency Treatment - methods | Anticoagulants - adverse effects | Outcome and Process Assessment (Health Care) | Pyrazoles - administration & dosage | Stroke - etiology | Quality Improvement | Antithrombins - adverse effects | Emergency Treatment - mortality | Pyridones - adverse effects | Cohort Studies | Stroke (Disease) | Warfarin | Diet therapy | Stroke patients | Atrial fibrillation
Cardiovascular | INTRAVENOUS THROMBOLYSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN ANTICOAGULATION | TISSUE-PLASMINOGEN ACTIVATOR | WARFARIN | ACUTE ISCHEMIC-STROKE | GUIDELINES | INTRACEREBRAL HEMORRHAGE | RISK SCORE | HEALTH-CARE PROFESSIONALS | INTRACRANIAL HEMORRHAGE | United States - epidemiology | Dabigatran - adverse effects | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Humans | Stroke - diagnosis | Warfarin - adverse effects | Male | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Medication Therapy Management - standards | Warfarin - administration & dosage | Rivaroxaban - administration & dosage | Thiazoles - adverse effects | Pyridones - administration & dosage | Pyridines - adverse effects | Rivaroxaban - adverse effects | Adult | Female | Registries | Stroke - therapy | Pyrazoles - adverse effects | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Emergency Treatment - methods | Anticoagulants - adverse effects | Outcome and Process Assessment (Health Care) | Pyrazoles - administration & dosage | Stroke - etiology | Quality Improvement | Antithrombins - adverse effects | Emergency Treatment - mortality | Pyridones - adverse effects | Cohort Studies | Stroke (Disease) | Warfarin | Diet therapy | Stroke patients | Atrial fibrillation
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 04/2015, Volume 35, Issue 4, pp. e39 - e50
The American College of Clinical Pharmacy (ACCP) previously published position statements on collaborative drug therapy management (CDTM) in 1997 and 2003....
collaborative practice | clinical pharmacy | comprehensive medication management | collaborative drug therapy management | clinical pharmacist | EVENTS | ECONOMIC EVALUATIONS | HOME PCMH | REFORM | TRIAL | PAY-FOR-PERFORMANCE | SAVINGS | PHARMACOLOGY & PHARMACY | CLINICAL PHARMACY SERVICES | HEALTH-CARE | PROGRAM | Legislation, Pharmacy | Patient-Centered Care - trends | United States | Humans | Drug Therapy | Patient Care Team | Patient-Centered Care - organization & administration | Pharmacy Service, Hospital - trends | Patient Protection and Affordable Care Act | Pharmacy Service, Hospital - organization & administration | Prescription drugs | Pharmacists | Drug therapy | Drug stores
collaborative practice | clinical pharmacy | comprehensive medication management | collaborative drug therapy management | clinical pharmacist | EVENTS | ECONOMIC EVALUATIONS | HOME PCMH | REFORM | TRIAL | PAY-FOR-PERFORMANCE | SAVINGS | PHARMACOLOGY & PHARMACY | CLINICAL PHARMACY SERVICES | HEALTH-CARE | PROGRAM | Legislation, Pharmacy | Patient-Centered Care - trends | United States | Humans | Drug Therapy | Patient Care Team | Patient-Centered Care - organization & administration | Pharmacy Service, Hospital - trends | Patient Protection and Affordable Care Act | Pharmacy Service, Hospital - organization & administration | Prescription drugs | Pharmacists | Drug therapy | Drug stores
Journal Article
The Journal of Cardiovascular Nursing, ISSN 0889-4655, 07/2017, Volume 32, Issue 4, pp. E9 - E23
INTRODUCTION:Coronary heart disease (CHD) is associated with significant morbidity and mortality, including mental health comorbidity, which is associated with...
DEPRESSION | CARDIAC & CARDIOVASCULAR SYSTEMS | self-management support | METAANALYSIS | Internet delivered intervention | NURSING | CARDIOVASCULAR-DISEASE | coronary heart disease | PHYSICAL-ACTIVITY | CARDIAC REHABILITATION | ehealth | INTERVENTION | Coronary Disease - rehabilitation | Medication Adherence - psychology | Humans | Self-Management - statistics & numerical data | Female | Male | Patient Participation - psychology | Internet | Coronary Disease - psychology | Patient Education as Topic - methods | Randomized Controlled Trials as Topic | Self Care - psychology | Online Only
DEPRESSION | CARDIAC & CARDIOVASCULAR SYSTEMS | self-management support | METAANALYSIS | Internet delivered intervention | NURSING | CARDIOVASCULAR-DISEASE | coronary heart disease | PHYSICAL-ACTIVITY | CARDIAC REHABILITATION | ehealth | INTERVENTION | Coronary Disease - rehabilitation | Medication Adherence - psychology | Humans | Self-Management - statistics & numerical data | Female | Male | Patient Participation - psychology | Internet | Coronary Disease - psychology | Patient Education as Topic - methods | Randomized Controlled Trials as Topic | Self Care - psychology | Online Only
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2017, Volume 70, Issue 14, pp. 1785 - 1822
In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density...
PCSK9 inhibitors | lipids | ASCVD | bile acid sequestrants | ezetimibe | LDL-C | statins | cholesterol | dyslipidemia | ACC Expert Consensus Decision Pathway | FAMILIAL HYPERCHOLESTEROLEMIA | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | HEART-FAILURE | SCIENTIFIC STATEMENT | REDUCING LIPIDS | DOUBLE-BLIND | EVOLOCUMAB | ROSUVASTATIN | Sequestering Agents - pharmacology | United States | Humans | Coronary Artery Disease - prevention & control | Enzyme Inhibitors - pharmacology | Ezetimibe - pharmacology | Cholesterol, LDL - analysis | Hypercholesterolemia - drug therapy | Consensus | Medication Therapy Management - organization & administration | Hypercholesterolemia - diagnosis | Anticholesteremic Agents - pharmacology | Cardiology - methods | Chemoprevention - methods | Decision-making | Usage | Task forces | Comorbidity | Low density lipoproteins | Coronary heart disease | Risk factors | Cardiovascular agents | Deoxycholic acid | Prevention | Hypercholesterolemia | Blood cholesterol | Cardiac patients | Diabetes | Universities and colleges | Cardiology | Statins | Lipoproteins (low density) | Clinical trials | Risk | Cardiovascular disease | Genetic screening | Atherosclerosis | Inhibition | Medical research | Risk groups | Decision making | Health risks | Subtilisin | Disease control | Patients | Low density lipoprotein | Cholesterol | Algorithms | Kexin | Inhibitors | Acids | Arteriosclerosis | Diagnostic systems | Cardiovascular diseases | Risk management
PCSK9 inhibitors | lipids | ASCVD | bile acid sequestrants | ezetimibe | LDL-C | statins | cholesterol | dyslipidemia | ACC Expert Consensus Decision Pathway | FAMILIAL HYPERCHOLESTEROLEMIA | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | HEART-FAILURE | SCIENTIFIC STATEMENT | REDUCING LIPIDS | DOUBLE-BLIND | EVOLOCUMAB | ROSUVASTATIN | Sequestering Agents - pharmacology | United States | Humans | Coronary Artery Disease - prevention & control | Enzyme Inhibitors - pharmacology | Ezetimibe - pharmacology | Cholesterol, LDL - analysis | Hypercholesterolemia - drug therapy | Consensus | Medication Therapy Management - organization & administration | Hypercholesterolemia - diagnosis | Anticholesteremic Agents - pharmacology | Cardiology - methods | Chemoprevention - methods | Decision-making | Usage | Task forces | Comorbidity | Low density lipoproteins | Coronary heart disease | Risk factors | Cardiovascular agents | Deoxycholic acid | Prevention | Hypercholesterolemia | Blood cholesterol | Cardiac patients | Diabetes | Universities and colleges | Cardiology | Statins | Lipoproteins (low density) | Clinical trials | Risk | Cardiovascular disease | Genetic screening | Atherosclerosis | Inhibition | Medical research | Risk groups | Decision making | Health risks | Subtilisin | Disease control | Patients | Low density lipoprotein | Cholesterol | Algorithms | Kexin | Inhibitors | Acids | Arteriosclerosis | Diagnostic systems | Cardiovascular diseases | Risk management
Journal Article
1998, ISBN 0727912747, xii, 196
Book
JAMA, ISSN 0098-7484, 07/2013, Volume 310, Issue 1, pp. 46 - 56
IMPORTANCE Only about half of patients with high blood pressure (BP) in the United States have their BP controlled. Practical, robust, and sustainable models...
URBAN AFRICAN-AMERICANS | IMPROVE | MEDICINE, GENERAL & INTERNAL | INTERVENTIONS | SELF-MANAGEMENT | PRIMARY-CARE | METAANALYSIS | HYPERTENSION CONTROL | CHRONIC ILLNESS | AMERICAN-HEART-ASSOCIATION | MEDICATION ADHERENCE | Blood Pressure | Diastole | Follow-Up Studies | Humans | Middle Aged | Male | Treatment Outcome | Combined Modality Therapy | Systole | Patient Satisfaction | Case Management | Telemedicine - methods | Female | Aged | Hypertension - therapy | Blood Pressure Monitoring, Ambulatory | Pharmacists | Usage | Telemedicine | Sphygmomanometer | Practice | Blood pressure | Regulation | Management | Research | Hypertension | Clinical trials | Disease control
URBAN AFRICAN-AMERICANS | IMPROVE | MEDICINE, GENERAL & INTERNAL | INTERVENTIONS | SELF-MANAGEMENT | PRIMARY-CARE | METAANALYSIS | HYPERTENSION CONTROL | CHRONIC ILLNESS | AMERICAN-HEART-ASSOCIATION | MEDICATION ADHERENCE | Blood Pressure | Diastole | Follow-Up Studies | Humans | Middle Aged | Male | Treatment Outcome | Combined Modality Therapy | Systole | Patient Satisfaction | Case Management | Telemedicine - methods | Female | Aged | Hypertension - therapy | Blood Pressure Monitoring, Ambulatory | Pharmacists | Usage | Telemedicine | Sphygmomanometer | Practice | Blood pressure | Regulation | Management | Research | Hypertension | Clinical trials | Disease control
Journal Article
Circulation, ISSN 0009-7322, 07/2015, Volume 132, Issue 3, pp. 167 - 173
Background The perioperative management of dabigatran in clinical practice is heterogeneous. We performed this study to evaluate the safety of perioperative...
dabigatran | medication adherence | hemorrhage | surgery | CARDIAC & CARDIOVASCULAR SYSTEMS | LONG-TERM ANTICOAGULATION | HEPARIN | ATRIAL-FIBRILLATION | REVERSAL | TRIAL | WARFARIN | ORAL ANTICOAGULANTS | ETEXILATE | PERIPHERAL VASCULAR DISEASE | INTERRUPTION | ELECTIVE SURGERY | Prospective Studies | beta-Alanine - blood | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Dabigatran | Benzimidazoles - administration & dosage | Thromboembolism - prevention & control | Aged, 80 and over | Female | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Benzimidazoles - blood | beta-Alanine - adverse effects | beta-Alanine - administration & dosage | Hemorrhage - blood | Thromboembolism - blood | Antithrombins - adverse effects | Antithrombins - blood | Perioperative Care - methods | Aged | Disease Management | Hemorrhage - chemically induced | Cohort Studies | Usage | Perioperative care | Surgery | Dabigatran etexilate | Dosage and administration | Management | Hemorrhage | Risk factors
dabigatran | medication adherence | hemorrhage | surgery | CARDIAC & CARDIOVASCULAR SYSTEMS | LONG-TERM ANTICOAGULATION | HEPARIN | ATRIAL-FIBRILLATION | REVERSAL | TRIAL | WARFARIN | ORAL ANTICOAGULANTS | ETEXILATE | PERIPHERAL VASCULAR DISEASE | INTERRUPTION | ELECTIVE SURGERY | Prospective Studies | beta-Alanine - blood | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Dabigatran | Benzimidazoles - administration & dosage | Thromboembolism - prevention & control | Aged, 80 and over | Female | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Benzimidazoles - blood | beta-Alanine - adverse effects | beta-Alanine - administration & dosage | Hemorrhage - blood | Thromboembolism - blood | Antithrombins - adverse effects | Antithrombins - blood | Perioperative Care - methods | Aged | Disease Management | Hemorrhage - chemically induced | Cohort Studies | Usage | Perioperative care | Surgery | Dabigatran etexilate | Dosage and administration | Management | Hemorrhage | Risk factors
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2010, Volume 153, Issue 8, pp. 507 - 515
Background: Resource barriers complicate diabetes care management. Support from peers may help patients manage their diabetes. Objective: To compare a...
MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | INTERVENTIONS | SELF-MANAGEMENT | METAANALYSIS | CHRONIC ILLNESS | DISEASE | SOCIAL SUPPORT | HEALTH | EDUCATION | INSULIN THERAPY | Blood Pressure | Self Efficacy | Telephone | Psychotherapy, Group - methods | Glycated Hemoglobin A - metabolism | Humans | Social Support | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - therapy | Medication Adherence | Motivation | Diabetes Mellitus, Type 1 - blood | Stress, Psychological | Diabetes Mellitus, Type 1 - nursing | Diabetes Mellitus, Type 1 - psychology | Insulin - therapeutic use | Psychological aspects | Care and treatment | Nursing care | Diabetes | Social aspects | Health aspects | Patient compliance | Methods | nurse case management | glycemic control | diabetes | self-management | peer support | randomized controlled trial
MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | INTERVENTIONS | SELF-MANAGEMENT | METAANALYSIS | CHRONIC ILLNESS | DISEASE | SOCIAL SUPPORT | HEALTH | EDUCATION | INSULIN THERAPY | Blood Pressure | Self Efficacy | Telephone | Psychotherapy, Group - methods | Glycated Hemoglobin A - metabolism | Humans | Social Support | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - therapy | Medication Adherence | Motivation | Diabetes Mellitus, Type 1 - blood | Stress, Psychological | Diabetes Mellitus, Type 1 - nursing | Diabetes Mellitus, Type 1 - psychology | Insulin - therapeutic use | Psychological aspects | Care and treatment | Nursing care | Diabetes | Social aspects | Health aspects | Patient compliance | Methods | nurse case management | glycemic control | diabetes | self-management | peer support | randomized controlled trial
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2013, Volume 61, Issue 4, pp. e78 - e140
An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist physicians in...
fibrinolysis | percutaneous coronary intervention | ST-elevation myocardial infarction | antiplatelets | anticoagulants | door-to-balloon | ACCF/AHA Practice Guidelines | reperfusion | CARDIAC & CARDIOVASCULAR SYSTEMS | HOSPITAL CARDIAC-ARREST | HEPARIN-INDUCED THROMBOCYTOPENIA | IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR | TISSUE-PLASMINOGEN-ACTIVATOR | EMERGENCY MEDICAL-SERVICES | LEFT-VENTRICULAR DYSFUNCTION | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | CATHETERIZATION LABORATORY ACTIVATION | Myocardial Infarction - diagnosis | Evidence-Based Medicine - methods | Myocardial Infarction - epidemiology | Risk Assessment | United States | Humans | Diagnostic Techniques, Cardiovascular | Clinical Protocols - standards | Cardiology - standards | Medication Therapy Management - standards | Myocardial Reperfusion - methods | Patient Selection | American Heart Association | Evidence-Based Medicine - standards | Myocardial Infarction - therapy | Emergency Medical Services - organization & administration | Thrombolytic Therapy | Coronary Artery Bypass | Electrocardiography | Clinical Protocols - classification | Disease Management | Emergency Medical Services - methods | Percutaneous Coronary Intervention | Cardiology - methods | Myocardial infarction | Decision support systems | Medical personnel | Anticoagulants | Enzymes | Task forces | Medical imaging | Heart attacks | Disease | Physicians | Heart surgery | Guidelines | Disease prevention | Hospitals | Risk assessment | Coronary vessels | Quality control | Infarction | Clinical medicine | Acute coronary syndromes | Cardiology | Drug therapy
fibrinolysis | percutaneous coronary intervention | ST-elevation myocardial infarction | antiplatelets | anticoagulants | door-to-balloon | ACCF/AHA Practice Guidelines | reperfusion | CARDIAC & CARDIOVASCULAR SYSTEMS | HOSPITAL CARDIAC-ARREST | HEPARIN-INDUCED THROMBOCYTOPENIA | IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR | TISSUE-PLASMINOGEN-ACTIVATOR | EMERGENCY MEDICAL-SERVICES | LEFT-VENTRICULAR DYSFUNCTION | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | CATHETERIZATION LABORATORY ACTIVATION | Myocardial Infarction - diagnosis | Evidence-Based Medicine - methods | Myocardial Infarction - epidemiology | Risk Assessment | United States | Humans | Diagnostic Techniques, Cardiovascular | Clinical Protocols - standards | Cardiology - standards | Medication Therapy Management - standards | Myocardial Reperfusion - methods | Patient Selection | American Heart Association | Evidence-Based Medicine - standards | Myocardial Infarction - therapy | Emergency Medical Services - organization & administration | Thrombolytic Therapy | Coronary Artery Bypass | Electrocardiography | Clinical Protocols - classification | Disease Management | Emergency Medical Services - methods | Percutaneous Coronary Intervention | Cardiology - methods | Myocardial infarction | Decision support systems | Medical personnel | Anticoagulants | Enzymes | Task forces | Medical imaging | Heart attacks | Disease | Physicians | Heart surgery | Guidelines | Disease prevention | Hospitals | Risk assessment | Coronary vessels | Quality control | Infarction | Clinical medicine | Acute coronary syndromes | Cardiology | Drug therapy
Journal Article
2006, 1, ISBN 9780849333231, xv, 211
Drug development is risky business. It is against the backdrop of huge financial, scientific, technical and medical risks that a clinical trials manager is...
Drugs | Clinical trials | Risk assessment | Testing | Clinical Trials - Pharmaceutical Science | Management - Pharmaceutical Science | Drug Discovery | Clinical trials - Risk assessment
Drugs | Clinical trials | Risk assessment | Testing | Clinical Trials - Pharmaceutical Science | Management - Pharmaceutical Science | Drug Discovery | Clinical trials - Risk assessment
Book
Pain Management Nursing, ISSN 1524-9042, 06/2018, Volume 19, Issue 3, pp. 207 - 210
Effective pain management requires careful titration of analgesics and evaluation of individual patient's responses to treatment using valid and reliable pain...
Societies, Nursing | Analgesics, Opioid | Inappropriate Prescribing - nursing | Chronic Pain - drug therapy | Practice Patterns, Nurses | Humans | Opioid-Related Disorders - prevention & control | Inappropriate Prescribing - prevention & control | Chronic Pain - nursing | Opioid-Related Disorders - nursing | Practice Guidelines as Topic | Care and treatment | Registered nurses | Pain | Nursing | Opioids | Societies | Medication errors | College teachers | Associations, institutions, etc
Societies, Nursing | Analgesics, Opioid | Inappropriate Prescribing - nursing | Chronic Pain - drug therapy | Practice Patterns, Nurses | Humans | Opioid-Related Disorders - prevention & control | Inappropriate Prescribing - prevention & control | Chronic Pain - nursing | Opioid-Related Disorders - nursing | Practice Guidelines as Topic | Care and treatment | Registered nurses | Pain | Nursing | Opioids | Societies | Medication errors | College teachers | Associations, institutions, etc
Journal Article
Circulation, ISSN 0009-7322, 01/2013, Volume 127, Issue 4, pp. e362 - e425
Anticoagulants | AHA scientific statements | Reperfusion | Antiplatelets | Percutaneous coronary intervention | St-elevation myocardial infarction | Door-to-balloon | Fibrinolysis | Thrombolysis | FREE-WALL RUPTURE | PERCUTANEOUS CORONARY INTERVENTION | CARDIAC & CARDIOVASCULAR SYSTEMS | DOOR-TO-BALLOON | TISSUE-PLASMINOGEN-ACTIVATOR | IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR | BUNDLE-BRANCH BLOCK | PERIPHERAL VASCULAR DISEASE | HOSPITAL CARDIAC-ARREST | AUTOMATED EXTERNAL DEFIBRILLATORS | RANDOMIZED CONTROLLED-TRIAL | CARDIOVASCULAR DATA REGISTRY | Myocardial Infarction - diagnosis | Evidence-Based Medicine - methods | Myocardial Infarction - epidemiology | Risk Assessment | United States | Humans | Diagnostic Techniques, Cardiovascular | Clinical Protocols - standards | Cardiology - standards | Medication Therapy Management - standards | Myocardial Reperfusion - methods | Patient Selection | American Heart Association | Evidence-Based Medicine - standards | Myocardial Infarction - therapy | Emergency Medical Services - organization & administration | Thrombolytic Therapy | Electrocardiography | Clinical Protocols - classification | Disease Management | Emergency Medical Services - methods | Percutaneous Coronary Intervention | Cardiology - methods | Usage | Care and treatment | Conferences, meetings and seminars | Medical societies | Practice guidelines (Medicine) | Heart attack | Standards
Journal Article